1. Home
  2. NSYS vs RNTX Comparison

NSYS vs RNTX Comparison

Compare NSYS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nortech Systems Incorporated

NSYS

Nortech Systems Incorporated

HOLD

Current Price

$9.05

Market Cap

25.5M

Sector

Technology

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.25

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSYS
RNTX
Founded
1981
2001
Country
United States
United States
Employees
744
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.5M
30.0M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
NSYS
RNTX
Price
$9.05
$1.25
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
5.0K
71.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,371,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.01
N/A
52 Week Low
$6.50
$1.02
52 Week High
$12.40
$2.27

Technical Indicators

Market Signals
Indicator
NSYS
RNTX
Relative Strength Index (RSI) 52.64 51.61
Support Level $8.86 $1.06
Resistance Level $9.82 $1.29
Average True Range (ATR) 0.45 0.10
MACD -0.08 0.01
Stochastic Oscillator 53.42 61.54

Price Performance

Historical Comparison
NSYS
RNTX

About NSYS Nortech Systems Incorporated

Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: